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A highly sensitive fluorimetric procedure based on alkylation of nicotinamide is described 
for the determination of aliphatic epoxides. Subsequent reaction of the resulting N-alkylni- 
cotinamides with a ketone in basic medium yields strongly fluorescent products after final 
acidification. Sensitivity of the assay is in the picomole range with good reproducibility. The 
alkylation reaction proceeds under physiological conditions and thus shows potential for the 
analysis of epoxides in biological materials. Despite rapid enzymatic detoxification, styrene 
oxide could be directly detected in 9000g supernatant liver fractions using the present approach. 
Aliphatic epoxides have been demon- 
strated to be intermediates in the biotrans- 
formation of several ethylenic compounds 
(l-4). Their high chemical reactivity ac- 
counts for such biological effects as muta- 
genesis (57), binding to cellular macro- 
molecules (g-IO), and alkylation of nucleic 
acids (11). Some epoxides are widely used 
in industry and thus represent potential haz- 
ards for exposed workers. 
So far, detection methods are restricted 
to gas-liquid chromatography (gc)’ (14) 
or a calorimetric p-nitrobenzylpyridine 
(NBP) approach (7,12,13). The gc method, 
while offering the advantage of specificity, 
requires extraction when it is applied to bi- 
ological materials, which might result in 
substantial degradation. Its sensitivity is 
generally limited to the nanomole range. The 
NBP method has improved sensitivity but 
with the disadvantage of instability of its 
final color. In addition, the reaction can only 
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be carried out in an essentially nonaqueous 
medium and is therefore incompatible with 
physiological conditions (7). 
In this paper, we describe a new, highly 
sensitive method for detecting epoxides, 
based on the alkylation of nicotinamide ( 14). 
Alkylated nicotinamides are converted to 
strongly fluorescent compounds following 
reaction with a ketone in basic medium and 
subsequent acidification (15-l 8). As the al- 
kylation reaction readily proceeds under 
physiologial conditions, it can be directly 
applied to biological materials. 
MATERIALS AND METHODS 
Propylene oxide, trichloropropylene oxide 
(1,2-epoxy-3,3,3-trichloropropane), epichlo- 
rohydrin, and cyclohexene oxide were ob- 
tained from the Aldrich Chemical Company 
(Milwaukee, Wise.) and styrene oxide from 
the Dow Chemical Company (Midland, 
Mich.). They were used as received. Nico- 
tinamide (Calbiochem, Los Angeles, Calif.) 
by tic on silica with propanol: 10% ammonia 
(95:5, v/v) showed a single spot with no in- 
dication of alkylated material at the origin. 
All other chemicals were analytical grade 
and purchased from MCB (Norwood, Ohio). 
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Preparation of epoxide solutions. Epoxide 
working solutions (0.1 pmol/ml) were pre- 
pared by diluting 2.0 ml of an ethanolic stock 
solution (1.25 pmol/ml) to 25.0 ml with 
0.0667 M phosphate buffer, pH 7.4. Further 
dilutions (up to 0.25 nmol/ml) were made 
in buffer as well. 
Assay of epoxides in aqueous solutions. 
One hundred microliters of the phosphate 
buffer solution containing 0.025-l 0 nmol of 
epoxide was mixed with 50 ~1 of nicotin- 
amide solution (125 ccmol/ml in 0.0667 M 
phosphate buffer, pH 7.4). After incubation 
for 15-120 min at 37°C (or, alternatively, 
at 60 or 80”(Z), 0.5 ml of acetophenone so- 
lution ( 15% v/v in ethanol) and 0.5 ml of 
1 M ethanolic potassium hydroxide was 
added. The contents of the tubes were im- 
mediately mixed and the mixture kept in ice 
for 10 min. Finally, 2.5 ml of formic acid 
(95-97s) was added and the tubes placed 
in a boiling water bath for 5 min and sub- 
sequently cooled in ice. The fluorescence is 
read and corrected for the contribution of 
a blank without epoxide after lo-15 min 
using an Aminco Bowman spectrofluori- 
meter with excitation and emission wave- 
lengths set at 370 and 430 nm, respectively. 
To increase the sensitivity, all volumes can 
be further reduced by a factor of 2 to 10. 
Detection of styrene oxide in liver ho- 
mogenates. The procedure described by 
Ames et al. ( 19) was followed to prepare rat 
S9 liver homogenates. S9 fractions were 
stored at -80°C until used. Diluted S9 
mixes were made by adding 1.4 mmol of 
nicotinamide and sufficient phosphate buffer 
(0.0667 M, pH 7.4) to 0.5 or 1.1 ml of S9 
fraction to bring the total volume to 2.1 ml. 
An aliquot of 0.3 ml of each S9 mixture 
(corresponding to 7 1 or 157 ~1 of S9 fraction, 
respectively) was combined with 0.5 ml of 
a buffered solution containing 0.10 or 0.42 
pmol of styrene oxide. Incubations were car- 
ried out at 37°C. Aliquots (50 ~1) were with- 
drawn after 30 min and assayed as described 
above. Control samples containing either 
boiled S9 fraction or buffer were run under 
the same conditions. 
To study the actual rate of disappearance 
of styrene oxide, the procedure was modified 
in that nicotinamide was omitted from the 
incubation mixture. Instead, 50-~1 aliquots 
were taken, then mixed with 100 ~1 of nic- 
otinamide solution and incubated for an ad- 
ditional 30 min at 80°C. All other steps re- 
mained unchanged. 
RESULTS 
Rate of Alkylation of Nicotinamide by 
Epoxides 
Three variables affect the rate of alkyla- 
tion of nicotinamide by aliphatic epoxides. 
Figure 1 illustrates the effect of the nicotin- 
amide concentration. Epichlorohydrin was 
used as a model compound for this experi- 
ment. Increasing amounts of the nucleophile 
increase the rate of alkylation and, therefore, 
enhance the final fluorescence, but at the 
expense of higher background. Reaction 
mixtures usually contained 6.25 or 12.5 rmol 
of nicotinamide. A linear relationship on 
log-log paper was found between fluores- 
cence after subtraction of the blank and the 
amount of nicotinamide over a wide range. 
1o-b. 1 100 
NICOTINAMIDE pmol 
FIG. 1. Effect of the amount of nicotinamide on the 
alkyiation rate by an aliphatic epoxide (epichlorohy- 
drin). Epoxide solutions (250 ~1, containing 12.5 nmol 
of epichlorohydrin) were incubated with 100 PI of a 
solution containing increasing amounts of nicotinamide. 
Fluorescence was developed as described under Mate- 
rials and Methods. 
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The effect of time and temperature in the 
alkylation of styrene oxide are shown in Fig. 
2. Although most results were obtained un- 
der physiological conditions, it was useful for 
the weakest alkylating agent in this study, 
i.e., cyclohexene oxide, to increase the tem- 
perature which resulted in faster alkylation 
and hence in an improvement of sensitivity. 
However, this trend was not confirmed for 
all the epoxides studied (Table 1). The ad- 
dition of an organic solvent such as ethanol 
to the reaction mixture had an unfavorable 
effect on the akylation rate. 
Assay of Epoxides in Aqueous Solution: 
Linearity and Sensitivity 
A linear response of fluorescence versus 
concentration was obtained for the four ep- 
oxides studied in the range of 0.5-50 nmol/ 
ml (trichloropropylene oxide), l-100 nmol/ 
ml (styrene oxide), 5-100 nmol/ml (cyclo- 
hexene oxide), and 1- 100 nmol/ml (propyl- 
ene oxide) (Table 2). 
Detection limits at 37 and 80°C are given 
in Table 1. A concentration corresponding 
to a fluorescence reading of twice the back- 
ground was defined as the lowest detectable 
amount, although the linear range usually 
extended below this value. Reduction of all 
volumes ( 10 ~1 of epoxide solution, 10 ~1 of 
nicotinamide solution, 25 ~1 of acetophenone 
50 100 MIN. 
FIG. 2. Effect of temperature and incubation time on 
the rate of alkylation of nicotinamide by styrene oxide. 
A styrene oxide solution (100 ~1, containing 5 nmol of 
compound) was reacted with 100 ~1 of a nicotinamide 
solution (I 2.5 pmol). 
TABLE I 
DETECTION LIMITS FOR FOUR EPOXIDES 







2.0 (200) 0.8 (78) 
0.5 (29) 0.6 (35) 
0.5 (60) 0.2 (24) 
0.1 (16) 0.09 (14.5) 
and KOH solutions, 130 ~1 of formic acid) 
further improved the sensitivity. Use of a 
microcell in this case allowed detection of 
as little as 0.025 nmol of trichloropropylene 
oxide. 
Detection of Styrene Oxide in S9 
Fractions 
Results of the assay of styrene oxide in an 
in vitro biological system containing S9 frac- 
tion are presented in Table 3. Reproduc- 
ibility at 30 min was evaluated on the basis 
of six determinations (50-~1 aliquots taken 
from six different samples). A concentration 
of 0.52 pmol/ml yielded a fluorescence read- 
ing of about five times the background. 
Longer incubation times failed to increase 
the fluorescence, indicating that all the ep- 
oxide had disappeared at this point, either 
by reaction with nicotinamide or because of 
enzymatic action. In order to monitor exclu- 
sively detoxification as a function of time, 
an alternative approach, without nicotin- 
amide in the incubation mixture, was em- 
ployed. Figure 3 shows fluorescence versus 
time plots for three concentrations of styrene 
oxide (0.05, 0.25, and 0.4 pmol/ml) in the 
presence of different amounts of S9 fraction. 
In previously deactivated (boiled) S9 prep- 
arations, the fluorescence remained constant 
over the same time interval and was essen- 
tially equal to the value obtained with the 
other control samples (buffer instead of S9 
fraction). 
DISCUSSION 
Nicotinamide in buffered aqueous solu- 
tion is readily alkylated by aliphatic epox- 
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TABLE 2 




















- - 12.5 
- 4.6 9.0 19.5 
1.5 15.0 44.0 
5.0 12.2 20.0 103.5 
6.3 14.0 47.0 204.0 
12.4 30.0 112.0 
23.7 50.0 220.0 930.0 
45.0 110.0 411.0 
Note. Equations of the fluorescence (ordinate) vs concentration curves werey = 0.43x + 2.3 (cyclohexene oxide), 
y  = 1.03x + 4.1 (propylene oxide), y  = 4.7x - 1.6 (styrene oxide), and y  = 18.5x + 5.8 (trichloropropylene oxide). 
Correlation coefficients were 0.9997, 0.9970, 0.9991, and 0.9998, respectively: 
* After subtraction of blank. 
ides. Ethylene oxide has been previously with ketones to give stable adducts after 
reported to yield N’-(2-hyroxyethyl)-nice acidification ( 15-18). Different cyclic struc- 
tinamide under similar conditions (14). In tures have been proposed for the reaction 
basic medium, N-alkylnicotinamides react product(s) (15,18,20). A high degree of 
TABLE 3 
















Mean + SD 
Coefficient of variation 
Background 
Controld 








a Results after subtraction of the background; after 30 min of incubation. 
b Incubation mixture (800 pi) containing 157 ~1 of S9 fraction and 200 pmol of nicotinamide. 
c Incubation mixture (800 ~1) containing 71 ~1 of S9 fraction and 200 rmol of nicotinamide. 
*Control samples contained buffer instead of S9 fraction. 
’ Results after subtraction of a blank value of 12. 
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specificity for alkylated nicotinamides is 
guaranteed, since both the presence of an 
amide group and a quaternary ring nitrogen 
are required for the reaction. The nature of 
the ketone determines the fluorescent prop- 
erties of the condensation product. Substi- 
tution of acetone by acetophenone resulted 
in a 5- to lo-fold increase in sensitivity. The 
same effect was noted previously for other 
IV-alkylnicotinamides, e.g., N-methylnico- 
tinamide ( 17,18). 
Although only a limited amount of nico- 
tinamide is actually alkylated by the epoxide 
and a competing solvolysis of the epoxide 
may be expected (21), the high sensitivity 
of the fluorimetric approach permits short 
reaction time (5 min for the more reactive 
halogenated compounds) under mild condi- 
tions (37°C). This represents major im- 
provement over the calorimetric NBP 
method. 
Furthermore, this fluorimetric assay pro- 
vides at least a loo-fold increase in sensitiv- 
ity. The latter extends beyond the nanomole 
range, whereas the average detection limit 
of the NBP method is estimated at 10 
nmol (13). 
The fluorescence of the final solution is 
reasonably stable over a long time, with only 
6% decrease being observed over a period of 
40 min. Application to biological materials 
does not require extraction or any sample 
pretreatment. Reproducibility of the assay 
even in biological media was highly satis- 
factory, and even at values as low as about 
twice the background (Table 3). While these 
S9-homogenate background values were 
somewhat higher than the corresponding 
buffer blanks, they were still reasonable even 
without centrifugation because of the rela- 
tively small amount of S9 fraction in the 
aliquots used for analysis. When turbidity 
occurred, centrifugation was included before 
measurement. Upon incubation of S9 frac- 
tions with styrene oxide in the presence of 
nicotinamide, competition occurs between 
alkylation and detoxification mechanisms, 
including enzymatic hydrolysis (22,23) and 
conjugation with glutathione (24). In addi- 
1 2 3 4 c MIN. 
FIG. 3. Rate of disappearance of styrene oxide from 
a 9000g supernatant (S9) system. Incubation mixtures 
(1 ml) contained either 100 (2 and 4) or 200 ~1 (1 and 
3) of S9 liver homogenate. Styrene oxide concentrations 
were 0.05 (1 and 2). 0.25 (3) and 0.4 pmol/ml (4). 
respectively. Aliquots (50 ~1) were taken at different 
times, mixed with 100 &I of a nicotinamide solution (12.5 
rmol), and incubated for 30 min at 80°C. 
tion a small amount of substrate might be 
covalently bound to tissue macromolecules 
(9). Despite the rapid disappearance of the 
substrate, it is clear that part of the epoxide 
is captured in the incubation medium by the 
nicotinamide. An estimation of the relative 
extent of the alkylation can be made by com- 
paring the fluorescence obtained for a bio- 
logical sample and the controls, respectively. 
From this, it can be inferred that the pres- 
ence of S9 fractions reduced the fluorescence 
to about 20% of the reading in the control 
samples, indicating that most of the epoxide 
has disappeared before it is capable of re- 
acting with the nicotinamide. Since alkyla- 
tion can only occur as long as free epoxide 
is available, this indicates that most of the 
epoxide has been deactivated either by bind- 
ing or enzymatic conversion. 
Study of the actual disappearance rate of 
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styrene oxide, using the modified approach, 
confirmed this rapid detoxification. After 
only a few minutes (Fig. 3), no more free 
substrate could be demonstrated. To date in 
the literature, hydratase activity and cou- 
pling with glutathione are separately mea- 
sured. The present method estimates the 
residual epoxide present following the 
combined action of all detoxification mech- 
anisms. Glutathione transferase activity is 
known to be considerably higher in S9 frac- 
tions than hydratase activity (24). This prob- 
ably accounts for the much shorter half-life 
of styrene oxide in the S9 fractions used in 
this study, as compared to microsomal prep- 
arations with their lower transferase levels. 
Furthermore, this phenomenon could be 
rationalized in terms of the low substrate 
concentrations used. Usually, lo- to 50-fold 
higher amounts of epoxide are required, e.g., 
in hydratase studies (23,25). Although other 
mechanisms such as noncovalent protein 
binding might contribute to the rapid dis- 
appearance of the substrate, no evidence 
presently exists as to the occurrence of such 
phenomena. The presence of albumin for 
example did not affect the fluorescence over 
a lo-min period. In addition, deactivated S9 
preparations always yielded the same results 
as control samples without liver fraction. 
The sensitivity of the method under phys- 
iological conditions makes it attractive for 
the possible in situ detection of epoxides, 
formed from alkene precursors. However, so 
far attempts failed to demonstrate any al- 
kylating activity in S9 mixtures incubated 
with styrene as a substrate. This was attrib- 
uted to the exceptionally high background, 
caused by the presence of the required co- 
factor NADPH. Oxidized NADP+, being an 
alkylated nicotinamide itself, could contrib- 
ute to the interfering fluorescence. This com- 
pound has been shown to yield a similar flu- 
orescent derivative as ZV-methylnicotinamide 
(26). In an attempt to test whether this in- 
deed was the case in our procedure, we used 
a glucose 6-phosphate dehydrogenase system 
to reverse the assumed conversion of 
NADPH to its oxidized form. However, the 
high fluorescent background remained un- 
affected by this addition. The work of 
Schenkman et al. (27) in which they noted 
that NADPH in the presence of microsomes 
was rapidly converted to an unidentified flu- 
orescent NADPH analog might explain the 
high background in our system. 
The method described in this paper is not 
specific for epoxides and could be extended 
to the detection of alkylating agents in gen- 
eral. It offers a dramatically increased sen- 
sitivity over existing assays. Its applicability 
to the S9-liver detoxification systems, with- 
out the need for any sample pretreatment, 
illustrates the attractiveness of the method 
for monitoring alkylating agents in an in 
vitro biological system. The small sample 
volume required permits multiple readings 
at different times, thus avoiding extraction 
of the whole incubation mixture. 
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